Since 1970, Candela has led the way in developing innovative new technologies for light-based aesthetic therapies. For nearly 40 years physicians and personal care professionals have looked to us for solutions they need to succeed. And more than any other company, Candela has delivered, with ground-breaking advances that have helped shape the industry as we know it. Innovations that include:
First vascular lesion treatment laser cleared for use on children.
First Q-switched alexandrite laser for pigmented lesions and tattoos.
First pulsed dye laser treatment to demonstrate effective treatment of hemangiomas, scars, warts and leg veins.
First laser cleared for the non-invasive treatment of acne and acne scars.
The introduction of the Dynamic Cooling Device (DCD) an epidermal protection system that remains a Candela exclusive
Integrated laser technologies that deliver the widest range of treatments in the industry.
Today, we offer the most comprehensive and technologically sophisticated aesthetic devices in the industry—a remarkably advanced portfolio of aesthetic lasers. Devices that offer proven speed, efficacy and ease-of-use in today’s most popular procedures, from permanent hair reduction, skin tightening and skin rejuvenation* to vascular and pigmented lesions and tattoo removal. Clearly other laser manufacturers agree—frequently comparing the performance of their devices to the high standards set by our products.
While other laser companies have come and gone, Candela continues to lead the way: Building upon our reputation as the most trusted partner of successful aesthetic practices; delivering innovation expertise and unwavering support to an installed base of more than 13,500 systems worldwide in 86 countries and 300 peer reviewed papers.
Specialties
Medical Devices, Aesthetic Devices, Laser Technology
New hires at Candela Corporation
Candela Corporation Activity on LinkedIn
-
Candela Corporation Syneron to Acquire Ultrashape Ltd.: "...Louis P. Scafuri, Chief Executive Officer of Syneron, said: "Ultrashape has developed a clinically validated, highly effective, customer- and patient-friendly product line focused on the non-invasive destruction of fat cells. The acquisition provides Syneron immediate entry into this large and attractive global market for fat disruptive body contouring and provides the opportunity to leverage our worldwide sales infrastructure and VelaShape installed-base to drive growth in the Ultrashape business..."
